Derivo embolization device in the treatment of unruptured intracranial aneurysms: a prospective multicenter study. (8th September 2020)

• Record Type: Journal Article
• Authors: Taschner, Christian A; Stracke, Christian Paul; Dorn, Franziska; Kadziolka, Krzysztof Bartosz; Kreiser, Kornelia; Solymosi, László; Pham, Mirko; Buhk, Jan Hendrik; Turowski, Bernd; Reith, Wolfgang; Elsheikh, Samer; Meckel, Stephan; Janssen, Hendrik; Hammer, Alexander; Beuing, Oliver; Jansen, Olav; Urbach, Horst; Knauth, Michael; Jenkner, Carolin; Chapot, René
• Is Part Of: Journal of neurointerventional surgery. Volume 13:Number 6(2021)
• Page Start: 541
• Page End: 546
• Publication Date: 2020-09-08
• Subjects: aneurysm -- flow diverter; Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2020-016303
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Background: Flow diverters (FD) are used regularly for the endovascular treatment of unruptured intracranial aneurysms. We aimed to assess the safety and effectiveness of the Derivo embolization device (DED) with respect to long-term clinical and angiographic outcomes. Methods: A prospective multicenter trial was conducted at 12 centers. Patients presenting with modified Rankin Score (mRS) of 0–1, treated for unruptured intracranial aneurysms with DED were eligible. Primary endpoint was the mRS assessed at 18 months with major morbidity defined as mRS 3–5. Satisfactory angiographic occlusion was defined as 3+4 on the Kamran scale. Results: Between July 2014 and February 2018, 119 patients were enrolled. Twenty-three patients were excluded. Ninety-six patients, 71 (74%) female, mean age 54±12.0 years, were included in the analysis. Mean aneurysm size was 14.2±16.9 mm. The mean number of devices implanted per patient was 1.2 (range 1–3). Clinical follow-up at 18 months was available in 90 (94%) patients, resulting in a mean follow-up period of 14.8±5.2 months. At last available follow-up of 96 enrolled patients, 91 (95%) remained mRS 0–1. The major morbidity rate (mRS 3–5) was 3.1% (3/96), major stroke rate was 4.2% (4/96), and mortality was 0%. Follow-up angiographies were available in 89 (93%) patients at a median of 12.4±5.84 months with a core laboratory adjudicated satisfactory aneurysm occlusion in 89% (79/89). Conclusion: Our results suggest that DED is a safe and effective treatment for unruptured aneurysms with high rates of satisfactory occlusion and comparably low rates of permanent neurological morbidity and mortality. Trial registration: DRKS00006103